Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 6/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.43 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7126943 | 0.88 | KIF11 (0.46) | MAOBMAPTSMN1; SMN2GAAGRIA1 | |
| SCHEMBL7128664 | 0.85 | GAA (0.58) | MAOBGAASMYD3PKMIDO1 | |
| SCHEMBL3135008 | 0.83 | MAOB (0.60) | MAOBGAASMYD3PKMIDO1 | |
| SCHEMBL688889 | 0.81 | CES1 (0.56) | MAOBGAAGRIA1CACNG8 | |
| SCHEMBL3249974 | 0.80 | GAA (0.54) | MAOBSMN1; SMN2GAASMYD3PKM | |
| SCHEMBL7122922 | 0.80 | GAA (0.53) | MAOBGAASMYD3PKMIDO1 | |
| SCHEMBL7122906 | 0.79 | MLNR (0.49) | MAOBMAPTSMN1; SMN2GAASMYD3 | |
| SCHEMBL7123207 | 0.79 | GAA (0.61) | MAPTGAASMYD3PKM | |
| SCHEMBL7114642 | 0.78 | GAA (0.50) | MAOBMAPTGAASMYD3PKM | |
| SCHEMBL7118311 | 0.78 | GAA (0.53) | MAOBMAPTGAAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6599902-B2 | For treating or preventing a protein kinase related disorder | SUGEN, INC. | 2003-07-29 | — | — | US | disclosed |
| US-20030125370-A1 | 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125370-A1 | 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | DMPK, ADK, MAP3K20 | MAOB 2166/4885MAPT 3167/4885SMN1; SMN2 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.